Science Explorer Back to mapMap

Most cited papers from Temple University Health System

What are the most cited papers from Temple University Health System?

The most cited paper from Temple University Health System is "Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer" (H. Borghaei et al., 2015), with 9,557 citations. Next come "Integrated genomic analyses of ovarian carcinoma" (8,268) and "Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018" (6,760).

Showing 50 of 60 papers. Every paper with more than 1,637 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer H. Borghaei et al. · New England Journal of Medicine Open access 27 Sep 2015 9,557
2 Integrated genomic analyses of ovarian carcinoma Debra Bell et al. · Nature Open access255 authors 28 Jun 2011 8,268
3 Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018 Lorenzo Galluzzi et al. · Cell Death and Differentiation Open access169 authors 23 Jan 2018 6,760
4 Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) Daniel J. Klionsky et al. · Autophagy Open access2,467 authors 2 Jan 2016 6,023
5 Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma Robert John Motzer et al. · New England Journal of Medicine Open access 25 Sep 2015 5,972
6 Comprehensive molecular profiling of lung adenocarcinoma Eric A. Collisson et al. · Nature Open access310 authors 8 Jul 2014 5,968
7 Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer Joan H. Schiller, David T. Harrington, Chandra Prakash Belani et al. · New England Journal of Medicine 10 Jan 2002 5,010
8 Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma Robert John Motzer et al. · New England Journal of Medicine Open access 21 Mar 2018 4,756
9 The 2015 World Health Organization Classification of Lung Tumors William David Travis, Elisabeth M. Brambilla, Andrew Gordon Nicholson et al. · Journal of Thoracic Oncology Open access 21 Aug 2015 4,651
10 Tolerance of normal tissue to therapeutic irradiation Bahman Emami, Jacqueline Lyman, Adam S. Brown et al. · International Journal of Radiation Oncology*Biology*Physics May 1991 4,510
11 Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors George D. Demetri et al. · New England Journal of Medicine Open access 15 Aug 2002 4,425
12 The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms Joseph David Khoury et al. · Leukemia Open access 22 Jun 2022 4,204
13 Comprehensive genomic characterization of squamous cell lung cancers Peter S. Hammerman et al. · Nature Open access339 authors 7 Sep 2012 4,071
14 A framework for advancing our understanding of cancer-associated fibroblasts Erik A. Sahai et al. · Nature reviews. Cancer ReviewOpen access 24 Jan 2020 3,962
15 Inflammation and Cancer: Triggers, Mechanisms, and Consequences Florian R. Greten, Sergei I. Grivennikov · Immunity Open access Jul 2019 3,881
16 The repertoire of mutational signatures in human cancer Ludmil B. Alexandrov et al. · Nature Open access1,384 authors 5 Feb 2020 3,854
17 Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma Gary R. Hudes, Michael Anthony Carducci, Piotr Tomczak et al. · New England Journal of Medicine 30 May 2007 3,671
18 Comprehensive molecular characterization of clear cell renal cell carcinoma Chad J. Creighton et al. · Nature Open access292 authors 23 Jun 2013 3,603
19 PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma Stephen Maxted Ansell, Alexander M. Lesokhin, Ivan Borrello et al. · New England Journal of Medicine Open access 6 Dec 2014 3,594
20 Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma Brian I. Rini et al. · New England Journal of Medicine Open access 16 Feb 2019 3,488
21 Pan-cancer analysis of whole genomes Lauri A. Aaltonen et al. · Nature Open access1,324 authors 5 Feb 2020 3,360
22 VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche Rosandra Natasha Kaplan et al. · Nature Open access Dec 2005 3,287
23 Concurrent Chemotherapy and Radiotherapy for Organ Preservation in Advanced Laryngeal Cancer Arlene A. Forastiere, Helmuth Goepfert, Moshe H Maor et al. · New England Journal of Medicine Open access 26 Nov 2003 3,192
24 Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden Matthew David Hellmann et al. · New England Journal of Medicine Open access 16 Apr 2018 3,185
25 Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers Karoline B. Kuchenbaecker et al. · JAMA Open access 20 Jun 2017 2,963
26 Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer Christopher J. Sweeney, Yu‐Hui Chen, Michael Anthony Carducci et al. · New England Journal of Medicine Open access 5 Aug 2015 2,915
27 Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer Matthew David Hellmann et al. · New England Journal of Medicine Open access 28 Sep 2019 2,901
28 Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children Alexander Edward Dela Cruz Drilon et al. · New England Journal of Medicine Open access 21 Feb 2018 2,827
29 Improved Survival of Patients With Human Papillomavirus-Positive Head and Neck Squamous Cell Carcinoma in a Prospective Clinical Trial Carole Fakhry, William H. Westra, S. Li et al. · JNCI Journal of the National Cancer Institute 12 Feb 2008 2,814
30 Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference Mack Roach, Gerald E. Hanks, Howard D. Thames et al. · International Journal of Radiation Oncology*Biology*Physics 24 Jun 2006 2,770
31 First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer David Paul Carbone et al. · New England Journal of Medicine Open access 21 Jun 2017 2,602
32 CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment Andy Trotti, A. D. Colevas, A. Setser et al. · Seminars in Radiation Oncology Jul 2003 2,589
33 The R.E.N.A.L. Nephrometry Score: A Comprehensive Standardized System for Quantitating Renal Tumor Size, Location and Depth Alexander Kutikov, Robert G. Uzzo · The Journal of Urology 18 Jul 2009 2,426
34 Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer Robert Allen Burger, Mark F. Brady, Michael A. Bookman et al. · New England Journal of Medicine Open access 28 Dec 2011 2,422
35 Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy Răzvan Cristescu et al. · Science Open access 11 Oct 2018 2,408
36 Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200 Bruce J. Giantonio, Paul J. Catalano, Neal J. Meropol et al. · Journal of Clinical Oncology 18 Apr 2007 2,283
37 Stereotactic body radiation therapy: The report of AAPM Task Group 101 Stanley Benedict et al. · Medical Physics 14 Jul 2010 2,228
38 A severe combined immunodeficiency mutation in the mouse Gayle C. Bosma, R. Philip Custer, Melvin J. Bosma · Nature Feb 1983 2,218
39 The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase Thomas F. Franke, Sung‐Il Yang, Tung O. Chan et al. · Cell Open access Jun 1995 2,033
40 The importance of glutathione in human disease Danyelle M. Townsend, Kenneth D. Tew, Haïm Tapiero · Biomedicine & Pharmacotherapy Open access May 2003 2,015
41 Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival James A. Bonner, Paul M. Harari, J. Giralt et al. · The Lancet Oncology 12 Nov 2009 1,984
42 The Immunological Genome Project: networks of gene expression in immune cells Tracy S P Heng et al. · Nature Immunology 18 Sep 2008 1,980
43 KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma Michael Wang et al. · New England Journal of Medicine Open access Apr 2020 1,874
44 Relationship of Circulating Tumor Cells to Tumor Response, Progression-Free Survival, and Overall Survival in Patients With Metastatic Colorectal Cancer Steven J. Cohen, Cornelis J.A. Punt, Nicholas O. Iannotti et al. · Journal of Clinical Oncology Open access 30 Jun 2008 1,863
45 Sotorasib for Lung Cancers with KRAS p.G12C Mutation Ferdinandos Skoulidis et al. · New England Journal of Medicine Open access 4 Jun 2021 1,862
46 The Tuberous Sclerosis Complex Peter B. Crino, Katherine L. Nathanson, Elizabeth P. Henske · New England Journal of Medicine 27 Sep 2006 1,793
47 Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology Al B. Benson et al. · Journal of the National Comprehensive Cancer Network Mar 2021 1,789
48 Identification of Distinct Basal and Luminal Subtypes of Muscle-Invasive Bladder Cancer with Different Sensitivities to Frontline Chemotherapy Woonyoung Choi, Sima P. Porten, Seungchan Kim et al. · Cancer Cell Open access Feb 2014 1,778
49 Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology Jaffer A. Ajani et al. · Journal of the National Comprehensive Cancer Network Open access Feb 2022 1,772
50 PISCES: a protein sequence culling server Guoli Wang, Roland L. Dunbrack · Bioinformatics Open access 11 Aug 2003 1,770

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.